Asia
Beijing Science Sun Pharmaceutical Gets China Approval for Blood Sugar Lowering Tablets
Beijing Science Sun Pharmaceutical (SHE:300485) subsidiary Beijing Saier Biopharmaceutical obtained registration and marketing authorization approval from China's National Medical Products Administration for its dapagliflozin tablets.The drug is an SGLT-2 inhibitor that helps lower blood glucose by promoting the excretion of glucose through the urine, according to a Tuesday disclosure to the Shenzhen bourse.
SHE:300485
